Last updated: July 10, 2026
Endo v. Actavis (1:12-cv-08985) Litigation Summary and Patent-Exclusivity Analysis
Endo Pharmaceuticals Inc. v. Actavis Inc., case number 1:12-cv-08985, is a federal Hatch-Waxman patent infringement dispute brought by Endo against Actavis. The litigation’s business impact is determined by (1) which asserted patents were litigated (drug substance, composition/formulation, and/or method-of-use), (2) whether Actavis pursued a Paragraph IV ANDA certification for a specific Endo product, and (3) whether the parties reached a settlement that governs generic launch timing.
No reliable, case-specific docket facts (asserted patent list, ANDA number, court disposition, dates, settlement terms, or claims construction) are present in the prompt, and producing a complete litigation summary without those items would be incomplete.
What is the case caption, court, and docket timeline for Endo Pharmaceuticals Inc. v. Actavis Inc. 1:12-cv-08985?
A litigation timeline requires docket-grounded events such as complaint filing date, answer and counterclaims, Rule 16 scheduling, claim construction milestones, expert deadlines, dispositive motion decisions, and trial dates. These are not available in the provided input.
What court heard the dispute and which parties were named?
A correct summary must include the federal district, the named plaintiffs/defendants, and any additional related parties (for example, generic ANDA filers, sublicensees, or parent companies). The prompt only provides the case number and the two core entities.
Which patents did Endo assert against Actavis in 1:12-cv-08985?
A meaningful infringement analysis depends on the precise list of asserted patents and their expiration dates, since Hatch-Waxman cases often involve multiple patent families. The prompt does not provide the asserted patent numbers, publication/application links, or Orange Book mappings.
How do the asserted patents typically break down in Endo v. Actavis cases?
Without the asserted list, the breakdown cannot be stated accurately. In practice, Endo estates often include:
- drug substance or active-ingredient synthesis/manufacturing patents
- composition/formulation patents (tablet formulation, coatings, excipients, dose forms)
- method-of-use patents (indications, dosing regimens, or patient subsets)
What is the expiration status of those patents by filing date and decision date?
Expiration status must be calculated per patent (including any adjustments or terminal disclaimers). No patent list is provided.
Was this a Paragraph IV ANDA challenge, and which ANDA product was at risk?
A Hatch-Waxman dispute is driven by an ANDA certification (Paragraph IV, I, II, III) and the reference listed drug (RLD). A litigation summary should identify:
- the RLD (Endo branded drug)
- the ANDA applicant (Actavis entity)
- the ANDA number
- the Orange Book patents targeted by the Paragraph IV notice
None of these identifiers are included in the prompt.
What did Actavis argue in response to Endo’s infringement claims (non-infringement, invalidity, or carve-outs)?
Litigation posture affects settlement likelihood and generic launch risk:
- invalidity arguments (anticipation, obviousness, lack of enablement, indefiniteness)
- non-infringement (process differences, formulation differences, lack of a critical limitation)
- statutory defenses (safe harbor, prosecution history estoppel)
No filings, claim charts, or decisions are provided.
What claim constructions and key rulings shaped the outcome?
A credible analysis should cite specific claim construction rulings and any summary judgment decisions on:
- claim term scope
- whether the accused product meets each limitation
- whether asserted claims are invalid
The prompt provides none of the claim construction or ruling content.
How did the court resolve the case in 1:12-cv-08985 (dismissal, judgment, or settlement dismissal)?
Resolution mode drives enforceability:
- final infringement judgment
- invalidity findings
- dismissal without prejudice
- settlement leading to dismissal or consent decree
No disposition or judgment entry is included.
If there was a settlement, what launch-trigger dates were set?
Settlement analysis depends on:
- agreed earlier/later launch dates
- payment terms if any (reverse payment risk analysis)
- entry carve-outs by dosage strength or formulation
No settlement terms are in the input.
What is the business impact: when does exclusivity end for Endo’s RLD involved in 1:12-cv-08985?
Exclusivity end-date analysis depends on:
- patent expiration dates (including PTA/PTE where applicable)
- regulatory exclusivities (NCE, pediatric exclusivity, orphan exclusivity if applicable)
- settlement-driven “blocking” periods beyond statutory exclusivity
No RLD, patents, or relevant regulatory exclusivity facts are provided.
What Orange Book patents are listed for the Endo RLD involved, and which were litigated?
Orange Book mapping is required to align litigated patents with listed patents and to identify which patents were actually asserted. Without the ANDA/RLD/patent list, no Orange Book status can be stated.
Which companies are challenging Endo’s product around the same period and how does Actavis compare?
Competitive landscape requires:
- other Paragraph IV filings by Actavis co-defendants or competitors
- the “first-filer” and “second-filer” status affecting 180-day exclusivity
- whether any competitors settled earlier
No linked case inventory is provided.
What generic entry risks exist after the 1:12-cv-08985 outcome?
Generic launch risk is a function of:
- remaining unexpired patents not asserted in this case
- whether Actavis’s entry would still infringe unlitigated patents
- formulation switch risks (design-around strategies)
No patent inventory is provided, and the case outcome is unknown.
How strong is Endo’s patent estate for the product implicated by 1:12-cv-08985?
Patent estate strength requires:
- number of families
- remaining time to expiration for each
- litigation outcomes across the estate
The input provides only the case number, not the estate composition.
Key Takeaways
- A litigation summary and patent-exclusivity analysis for Endo Pharmaceuticals Inc. v. Actavis Inc., 1:12-cv-08985 requires docket-specific facts (asserted patents, ANDA/RLD linkage, claim constructions, and disposition).
- The prompt does not include those facts, so a complete and accurate litigation analysis cannot be produced from the information provided.
FAQs
- What patents are commonly asserted by Endo in Hatch-Waxman actions against Actavis?
- How does Paragraph IV status change the 180-day exclusivity timeline for a generic entrant?
- What claim-construction issues most often determine outcomes in generic infringement cases?
- How do settlement dismissals typically structure launch dates across multiple strengths or formulations?
- What Orange Book mechanisms determine which listed patents can block generic entry after litigation?
References
- None cited.
